ChadiNabhanMDMBA, FACP

Hematologic Oncology

Chairman; Precision Oncology Alliance; Caris Life Sciences. Adjunct Professor; University of South Carolina; Department of Clinical Pharmacy and Outcomes Sciences.

Join to view full profile

Dr. Nabhan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Nabhan's full profile

Already have an account?

Office
974 Bristol Dr
Deerfield, IL 60015
Phone+1 312-927-3327

Education & Training

Loyola Quinlan School of BuisnessMBA, Health Care Management, Magna Cum Laude, 2014 - 2016
McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 1999 - 2002
Loyola University Medical CenterResidency, Internal Medicine, 1995 - 1998
Damascus University Faculty of MedicineClass of 1991

Certifications & Licensure

FL State Medical License 2008 - 2026
IL State Medical License 1995 - 2026
CA State Medical License 2015 - 2025
IN State Medical License 1999 - 2025
WI State Medical License 1997 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
National Board of Physicians and Surgeons Hematology
National Board of Physicians and Surgeons Internal Medicine
National Board of Physicians and Surgeons Medical Oncology

Awards, Honors, & Recognition

Chicago Top Doctors 2016
Regional Top Doctor Castle Connolly, 2014
Top MD Consumers Checkbook

Clinical Trials

GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere Start of enrollment: 2006 Jan 01
Completed
Phase 2
Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer Start of enrollment: 2006 Dec 01
Completed
Phase 1, Phase 2
Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC) Start of enrollment: 2007 Jan 01
Completed
Phase 1
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients Start of enrollment: 2008 Feb 01
Completed
Phase 2
Non-Hodgkin Lymphoma in Elderly Patients Above the Age of 80 in the Rituximab Era Start of enrollment: 2009 May 01
Completed
Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients Start of enrollment: 2009 Jun 01
Completed
Phase 2
Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas Start of enrollment: 2010 Feb 01
Terminated
Phase 2
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2011 Aug 01
Completed
Phase 2
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Start of enrollment: 2013 Mar 05
Terminated
Phase 1, Phase 2
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer Start of enrollment: 2014 May 01
Completed
Phase 2
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas Start of enrollment: 2014 Jul 29
Active, not recruiting
Phase 1, Phase 2
Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer Start of enrollment: 2016 Feb 01
Terminated
Phase 2
Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma Start of enrollment: 2016 May 13
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

3 citations
Opposing Roles ofMutations in Human Prostate and Endometrial Cancers.
Ludimila Cavalcante, Sachin Kumar Deshmukh, Jennifer R Ribeiro, Benedito A Carneiro, Don S Dizon
JCO Precision Oncology. 2023-09-01
53 citations
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.
Anthony R. Mato, Lindsey E. Roeker, John N. Allan, John M. Pagel, Danielle M. Brander
American Journal of Hematology. 2018-11-01
54 citations
Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study.
Narendranath Epperla, Mehdi Hamadani, Amanda F. Cashen, Kwang Woo Ahn, Eunhye Oak
Hematological Oncology. 2017-01-08

Journal Articles

Rethinking Clinical Trials Reform During the COVID-19 Pandemic
Chadi Nabhan, Toni K Choueiri, JAMA Oncology

Abstracts/Posters

Utilization of Immune Checkpoint Inhibitors for Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) in Oncology Community Practices
Chadi Nabhan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Adverse Events in Elderly Hodgkin Lymphoma Patients Treated with Pembrolizumab or Nivolumab in the Real World
Chadi Nabhan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
Chadi Nabhan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Frequency and causes of oncologistsâ€™ burnout in community practices.
2019 ASCO Annual Meeting - 6/1/2019
Patient-Reported Outcome Labeling for Malignant Hematology Drugs Approved in the United States: 2011-2017
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Treatment Patterns and Outcomes of Relapsed/Refractory Peripheral T-Cell Lymphoma (RR-PTCL) Patients Treated in the Community Oncology Setting
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Management and outcomes of 222 CLL patients (pts) treated with venetoclax (VEN) in the real world.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Overall survival (OS) and transplantation (ASCT) utilization in real-world patients with relapsed/refractory diffuse large B-cell lymphoma (RR-DLBCL).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Join now to see all

Authored Content

Rethinking Clinical Trials Reform During the COVID-19 PandemicAugust 2020
Rethinking Clinical Trials Reform During the COVID-19 PandemicAugust 2020

Press Mentions

Caris Life Sciences to Showcase Research Highlighting the Clinical Value of Comprehensive Molecular Profiling at the American Association for Cancer Research Annual MeetingApril 14th, 2023
The Caris Precision Oncology Alliance Welcomes University of Chicago Medicine Comprehensive Cancer CenterMarch 8th, 2023
Caris Life Sciences to Showcase Extensive Research with Leading Cancer Centers at ASCO Gastrointestinal Cancers Symposium 2023 Reflecting Its Commitment to Improving Outcomes for PatientsJanuary 18th, 2023
Join now to see all